PBAC Public Summary Documents – July 2018
Page last updated: 15 March 2019
Public Summary Documents relating to the July 2018 PBAC meeting.
- Adalimumab: Injection 20 mg in 0.4 mL pre-filled syringe; Injection 40 mg in 0.8 mL pre-filled syringe; Injection 40 mg in 0.8 mL pre-filled pen; Amgevita®
- Adalimumab: Injection 40 mg in 0.8 mL pre-filled syringe; Injection 40 mg in 0.8 mL single dose autoinjector; Hadlima®
- Adalimumab: Injection 20 mg in 0.2 mL pre-filled syringe; Injection 80 mg in 0.8 mL pre-filled pen; Humira®
- Apomorphine: Injection containing apomorphine hydrochloride 30 mg in 3 ml cartridge; Apomine® Intermittent
- Aripiprazole: Powder for injection 400 mg (as monohydrate) with diluent, pre-filled syringe; Abilify Maintena®
- Avelumab: Solution concentrate for I.V. infusion 200 mg in 10 mL; Bavencio®
- Bezlotoxumab: Solution concentrate for I.V. infusion 1000 mg in 40 ml; Zinplava®
- Blinatumomab: Powder for I.V. infusion 38.5 micrograms; Blincyto®
- Botulinum toxin type A: Lyophilised powder for injection 100 units; Botox®
- Brentuximab vedotin: Powder for I.V. infusion 50 mg; Adcetris®
- Budesonide: Capsule (modified release) 3 mg; Entocort®
- Carmellose sodium hypromellose: Eye drops containing carmellose sodium 5 mg per ml, 10 ml (Evolve carmellose); Eye drops containing hypromellose, 3 mg per ml, 10 ml (Evolve hypromellose); Evolve® carmellose, Evolve® hypromellose
- Cerliponase alfa: Solution for infusion 150 mg with flushing solution; Brineura®
- Cladribine: Tablet 10 mg; Mavenclad®
- Clozapine; Oral liquid 50 mg per mL, 100 mL; Versacloz®
- Crizotinib: Capsule 200 mg; Capsule 250 mg; Xalkori®
- Deferasirox: Tablet 90 mg; Tablet 180 mg; Tablet 360 mg; Jadenu®
- Denosumab: Injection 120 mg in 1.7 mL; Xgeva®
- Dolutegravir + rilpivirine: Tablet containing dolutegravir 50 mg with rilpivirine 25 mg; Juluca®
- Dupilumab: Injection 300 mg in 2 mL single dose pre-filled syringe; Dupixent®
- Erenumab: Injection 70 mg in 1 mL single dose pre-filled pen; Aimovig®
- Hepatitis B surface antigen recombinant vaccine: Injection 20 micrograms in 1 mL vial; Engerix-B®
- Ertugliflozin with sitagliptin: Tablet containing 5 mg ertugliflozin with 100 mg sitagliptin (as phosphate monohydrate); Tablet containing 15 mg ertugliflozin with 100 mg sitagliptin (as phosphate monohydrate); 2. Ertugliflozin: Ertugliflozin tablet 5 mg; Ertugliflozin tablet 15 mg; 3. Ertugliflozin + metformin: Tablet containing 2.5 mg ertugliflozin with 500 mg metformin hydrochloride; Tablet containing 2.5 mg ertugliflozin with 1 g metformin hydrochloride; Tablet containing 7.5 mg ertugliflozin with 500 mg metformin hydrochloride; Tablet containing 7.5 mg ertugliflozin with 1 g metformin hydrochloride; 4. Sitagliptin: Sitagliptin tablet 25 mg (as phosphate monohydrate); Sitagliptin tablet 50 mg (as phosphate monohydrate); Sitagliptin tablet 100 mg (as phosphate monohydrate); 5. Sitagliptin + metformin: Tablet containing 50 mg sitagliptin (as phosphate monohydrate) with 500 mg metformin hydrochloride; Tablet containing 50 mg sitagliptin (as phosphate monohydrate) with 850 mg metformin hydrochloride; Tablet (modified release) containing 50 mg sitagliptin (as phosphate monohydrate) with 1000 mg metformin hydrochloride; Tablet (modified release) containing 100 mg sitagliptin (as phosphate monohydrate) with 1000 mg metformin hydrochloride; 1. Stenglujan®, 2. Steglatro®, 3. Segluromet®, 4. Januvia®; 5. Janumet®, Janumet XR®
- Ertugliflozin: Tablet containing 15 mg ertugliflozin; Steglatro®; Ertugliflozin with metformin: Tablet containing 7.5 mg ertugliflozin with 500 mg metformin hydrochloride; Tablet containing 7.5 mg ertugliflozin with 1 g metformin hydrochloride; Segluromet®
- Evolocumab: Injection 140 mg in 1 ml single use pre-filled pen; Injection 420 mg in 3.5 ml single use pre-filled cartridge; Repatha®
- Ferric derisomaltose: Injection 500 mg (iron) in 5 mL; Monofer®
- Golimumab: Injection 50 mg in 0.5 ml single use pre‑filled syringe (Simponi); Injection 50 mg in 0.5 ml single use pre‑filled pen (Simponi Smartject); Simponi®, Simponi Smartject®
- Guanfacine: Tablet containing guanfacine hydrochloride 1 mg; Tablet containing guanfacine hydrochloride 2 mg; Tablet containing guanfacine hydrochloride 3 mg; Tablet containing guanfacine hydrochloride 4 mg; Intuniv®
- Imatinib: Tablet 100 mg, Capsule 100 mg, Tablet 400 mg, Capsule 400 mg; Multiple Brands
- Insect allergen extract-honey bee venom: Injection set containing 550 micrograms with diluent; 2. Insect allergen extract-paper wasp venom: Injection set containing 550 micrograms with diluent, 3. Insect allergen extract-yellow jacket venom: Injection set containing 550 micrograms with diluent; 1. Hymenoptera Honey Bee Venom®, 2. Hymenoptera Paper Wasp Venom®, 3. Hymenoptera Yellow Jacket Venom®
- Insulin glargine: Injections (human analogue), cartridges, 100 units per ml, 3 ml, 5; Semglee®
- Ixekizumab: Injection 80 mg in 1 ml single dose pre-filled pen; Injection 80 mg in 1 ml single dose pre-filled syringe; Taltz®
- Lenvatinib (HCC): Capsule 4 mg (as mesilate); Lenvima®
- Lenvatinib (thyroid cancer): Capsule 4 mg (as mesilate); Capsule 10 mg (as mesilate); Lenvima®
- Letermovir: Tablet 240 mg; Prevymis®
- Lumacaftor with ivacaftor (aged 6 – 11 years): Tablet containing lumacaftor 100 mg with ivacaftor 125 mg; Orkambi®
- Lumacaftor with ivacaftor (aged 12+ years): Tablet containing lumacaftor 200 mg with ivacaftor 125 mg; Orkambi®
- Meningococcal (groups A, C, W-135 and Y) oligosaccharide CRM 197 conjugate vaccine: Injection 0.5mL combination pack; Menveo®
- Mesalazine: Tablet 1 g (enteric coated); Salofalk®
- Methotrexate: Injection 7.5 mg in 0.3 mL pre-filled syringe; Injection 10 mg in 0.4 mL pre-filled syringe; Injection 15 mg in 0.6 mL pre-filled syringe; Injection 20 mg in 0.8 mL pre-filled syringe; Injection 25 mg in 1 mL pre-filled syringe; Methoblastin® PFS
- Midostaurin: Capsule 25 mg; Rydapt®
- Nivolumab and ipilimumab (malignant melanoma): Nivolumab: Injection concentrate for I.V. infusion 40 mg in 4 mL; Injection concentrate for I.V. infusion 100 mg in 10 mL; Ipilimumab: Injection concentrate for I.V. infusion 50 mg in 10 mL; Injection concentrate for I.V. infusion 200 mg in 40 mL; Opdivo® and Yervoy®
- Nivolumab and ipilimumab (renal cell carcinoma): Nivolumab: Injection concentrate for I.V. infusion 40 mg in 4 mL; Injection concentrate for I.V. infusion 100 mg in 10 mL; Ipilimumab: Injection concentrate for I.V. infusion 50 mg in 10 mL; Injection concentrate for I.V. infusion 200 mg in 40 mL; Opdivo® and Yervoy® - updated 15 March 2019
- Nivolumab (malignant melanoma): Injection concentrate for I.V. infusion 40 mg in 4 mL; Injection concentrate for I.V. infusion 100 mg in 10 ml; Opdivo®
- Nusinersen: Solution for injection 12 mg in 5 mL; Spinraza®
- Obinutuzumab: Solution for I.V. infusion 1000 mg in 40 mL; Gazyva®
- Octreotide: Injection (modified release) 10 mg (as acetate); Vial and diluent syringeinjection (modified release) 20 mg (as acetate); Vial and diluent syringeinjection (modified release) 30 mg (as acetate); Vial and diluent syringe; Sandostatin LAR®
- Osimertinib: Tablet 40 mg, Tablet 80 mg; Tagrisso®
- Pegfilgrastim: Injection 6 mg in 0.6 ml single use pre-filled syringe; Fulphila® - updated 1 March 2019
- Pembrolizumab (urothelial cancer): Solution concentrate for I.V. infusion 100 mg in 4 mL; Keytruda®
- Pembrolizumab (NSCLC): Powder for injection 50 mg; Solution concentrate for I.V. infusion 100 mg in 4 mL; Keytruda®
- Pembrolizumab (SCCHN): Solution concentrate for I.V. infusion 100 mg in 4 ml; Keytruda®
- Pertuzumab: Solution for I.V. infusion 420 mg in 14 ml; Perjeta®
- Somatropin: Solution for injection 5 mg (15 i.u.) in 1.5 ml cartridge (with preservative); SciTropin A™
- Teduglutide; Powder for injection 5 mg with diluent; Revestive®
- Tildrakizumab: Injection 100 mg in 1 mL single use pre-filled syringes; Ilumya®
- Tocilizumab: Injection 162 mg in 0.9 ml pre-filled pen; Actemra® Subcutaneous Injection
- Tolvaptan: Pack containing 28 tablets 15 mg and 28 tablets 45 mg; Pack containing 28 tablets 30 mg and 28 tablets 60 mg; Pack containing 28 tablets 30 mg and 28 tablets 90 mg; Jinarc®
- Trifluridine with tipiracil: Tablet containing 15 mg trifluridine with 6.14 mg tipiracil (as hydrochloride); Tablet containing 20 mg trifluridine with 8.19 mg tipiracil (as hydrochloride); Lonsurf®
- Triglycerides medium chain formula: Sachets containing oral powder 16 g, 30 (MCT Pro-Cal); MCT Pro-Cal
- Trivalent influenza vaccine (high dose); Injection 0.5 mL; Fluzone® High-Dose
- Zoledronic acid: Injection concentrate for I.V. infusion 4 mg (as monohydrate) in 5 mL, 5 vials; Claris Lifesciences Zoledronic Acid®
The following Public Summary Documents have been updated based on outcomes from the July 2018 meeting.
March 2018 PBAC meeting
- Bictegravir + emtricitabine + tenofovir alafenamide fixed dose combination: Tablet containing tenofovir alafenamide 25 mg with emtricitabine 200 mg and bictegravir 50 mg; Biktarvy®
- Guselkumab: Injection 100 mg in 1 mL single use pre-filled syringe; Tremfya®Quetiapine: Tablet 25 mg (as fumarate); Multiple Brands
- Sofosbuvir with velpatasvir and voxilaprevir: 400mg/100mg/100mg tablets; VOSEVI®
December 2017 PBAC meeting
November 2017 PBAC meeting
- Amino acid formula with vitamins, minerals and long chain polyunsaturated fatty acids, without phenylalanine: Oral powder 400 g (PKU Start); PKU Start®
- Lanreotide (GEP-NETs): Injection 120 mg (as acetate) in single dose pre-filled syringe; Somatuline® Autogel®
July 2017 PBAC meeting
